At a press conference, BDI Vice President Arta Bilalli-Zendeli said that Phoenix Pharma in Macedonia had come under the control of a Serbian businessman from the casino and betting industry.
According to her, on April 3, 2025, the Commission for the Protection of Competition approved the acquisition of Phoenix Pharma by the Serbian company VEGA through decision No. 08-55. She said the company is linked to Dejan Çakajac, a co-owner of the gambling company Mozzart.
Të lidhura
None found
Bilalli-Zendeli noted that in 2026 alone, Vega Farmaceutikals secured more than 50 public contracts with the Ministry of Health and various clinics, worth millions of euros. According to her, around 10 million euros of that amount is for insulin. She claimed that the institution responsible for protecting competition had allowed a supplier with a dominant position in insulin tenders to come under the control of a Serbian gambling businessman.
She stressed that insulin is a life-saving medicine and that its supply is a matter of the country’s health security, not an ordinary commercial activity. She therefore asked who had assessed the risk to the insulin supply, why the Commission had approved the acquisition and whether the decision had been politically influenced. She also asked whether Valon Elezi, VLEN’s member on the Commission, was aware of the matter.
The BDI vice president called for the full analysis on which the transaction was approved to be made public, along with all insulin contracts for the period 2025–2027. She raised concerns that, after banks and telecommunications, control over insulin was now also at issue: banks are tied to citizens’ money, telecommunications to their communications, and insulin to people’s lives. According to her, if the company faces problems in Serbia, the country’s supply of medicines and insulin could be put at risk.






